Skip to main content
. 2016 Nov 23;8(1):999–1006. doi: 10.18632/oncotarget.13533

Figure 2. Patients with tumors demonstrating TGFβ1 expression ≥75th percentile (high TGFβ1) have longer median survival than other patients (> 60 vs 17 months, P = 0.005).

Figure 2